Roche's COVID-19 antibody cocktail now available in India, marketed by Cipla
The Indian subsidiary of Swiss pharma major Roche (ROG: SIX) and domestic drugmaker Cipla Limited (BSE: 500087) today announced that the first batch of the Roche antibody cocktail (casirivimab and imdevimab) is now available in India, while a second batch will be made available by mid-June.
In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients, said Cipla. Financial aspects of the collaboration are not disclosed.
Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID-19 treatment centers. The Central Drugs Standards Control Organization (CDSCO) had recently provided an Emergency Use Authorization (EUA) for the antibody cocktail in India. It has also received a EUA in the USA and several EU countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze